my account
log out
|
|
my account
log out
|
Anti-ERBB2 (Trastuzumab-LC-R142)-DBCO-MMAF ADC |
| Create: 09/27/2017 |
| Expired Date: | never |
| Category: | Drugs&Pharmaceutical [Health&Medical&Pharmaceutical] |
| Message: | This ADC product is comprised of an anti-ERBB2 monoclonal antibody (Trastuzumab variant,LC-R142) conjugated via a DBCO linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death. https://www.creative-biolabs.com/adc/target-erbb2-37.htm |
 | |
| City: | Chengdu Sichuan[US]
 |
| Location: |
|
| Feb 01 2023 | VBS++ (with Ca and Mg) Buffer | 269 | |
| Feb 01 2023 | GVBE Buffer | 277 | |
| Feb 01 2023 | GVB++ (with Ca and Mg) Buffer | 277 | |
| Feb 01 2023 | Hemolysin (Rabbit Anti-Sheep Cell Hemolysin) | 272 | |
| Aug 30 2019 |  | Anti-HSV-2 gH Antibody | 462 |
| Aug 30 2019 | | Anti-L. major LPG Antibody | 544 |
| Aug 30 2019 | | Anti-DENV-1 Antibody | 452 |
| Aug 30 2019 | | Anti-BPV-1 L1 Antibody | 466 |
| Aug 30 2019 | | Anti-H3N2 HA Antibody | 454 |
| Aug 30 2019 | | Anti-EIAV env Antibody | 475 |
| Copyright © toextrade Inc. All rights reserved. Contact us |